Checking a Peptide Vendor's Public Pages: A Five-Minute Method

Updated August 21, 2026

The FDA warning letters issued to research-peptide sellers in December 2024 and March 2026 record exactly what the agency read before writing: product pages, cart contents, product names, and social accounts. Those four sources convert into a public-page review any buyer can run in about five minutes, using nothing but what a vendor publishes.

Where the checks come from

This page recommends no vendor and rates none. It does one thing: it takes the evidence categories named in the four letters of December 10, 2024 and the seven letters of March 31, 2026, and turns each category into a check. The letters are unusually explicit about their own inputs — each one names what was reviewed and where — so the checklist writes itself from the record.

The five-minute review

Minutes 1–2 — product pages. Open three product listings and read the description text for statements about what the compound does in a person. This is the category the March 2026 letters cite most: therapeutic-effect descriptions sitting on the same page as research-use disclaimers. The agency's quoted position on that pairing — despite the disclaimers, "evidence obtained from your website establishes that your products are intended to be drugs for human use."
Minute 3 — the cart. Look at what else the store sells. The March 2026 letters cited administration supplies offered in the same cart as the compounds, and the composition of the cart entered the record as intended-use evidence on its own. No written claim was required for the pairing to count.
Minute 4 — product names. Compare the listing names against standard compound nomenclature. Coverage of the March 2026 batch documents coded designations — "GLP-1 SM," "GLP-3 RT" — in place of recognized names. Per the letters, the agency read the coding as circumvention, not caution.
Minute 5 — social accounts. Check the seller's own accounts, because the letters did. One December 2024 letter cited a post from the recipient's Facebook account as intended-use evidence, weighed in the same pile as the product catalog. A storefront and its social feed form one body of evidence, not two.

Why the checks aggregate

The pattern across both batches is that no single page decides the question. Every recipient carried a research-use disclaimer somewhere. The letters were built from the rest of the footprint — a description here, a cart pairing there, a named post — assembled into one intended-use finding. A buyer running the review should read the four checks the same way: together.

What a clean result means, and what it does not

This review reproduces the evidence categories the 2024–2026 letters name. It does not reproduce the agency's judgment, and it is not a legal opinion. A vendor whose public pages show none of the four patterns has a footprint unlike the documented letter recipients' — a factual observation, nothing more. It is not agency clearance, and no list of cleared vendors follows from it; this index keeps none. What the review is good for is narrower and still useful: five minutes with a vendor's own pages tells you whether its public record resembles the record FDA has been writing letters about. Entity-by-entity records of those letters, the raids, and the closures are kept in the Vendor Closure and Enforcement Index.

A limit on the check itself: finding no letter for a vendor means no letter came back from that index on the day you searched. This index has recorded a published letter disappearing from FDA's index for four nights and returning with different redactions, so an absence is worth dating rather than treating as settled.

Sources